Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited develops epigenetics-based diagnostics through its Nucleosomics platform, which measures nucleosomes in blood and other bodily fluids. The company’s Nu.Q® product portfolio spans human diagnostics and monitoring for cancer, sepsis, trauma biomarker research and other disease areas, as well as veterinary oncology through Nu.Q® Vet assays.
VNRX news covers clinical publications and assay-development milestones, commercialization of Nu.Q® tests, veterinary cancer-test development, recombinant nucleosome products under rNuQ™, licensing and distribution activity, financial results, non-dilutive funding, equity financing and NYSE American listing-compliance matters. Volition’s research and development activities are centered in Belgium, with additional operations in the United States and London.
VolitionRx (NYSE AMERICAN: VNRX) has achieved a significant breakthrough in medical diagnostics by developing a lateral flow test that can quantify nucleosomes in whole venous blood within minutes. The company conducted a blinded study under the SUMMIT program, testing blood samples from 25 hospital patients in Intensive Care and Emergency Departments.
The new test shows strong correlation with Volition's established Nu.Q® nucleosome assay, enabling rapid detection of immune disruptions associated with conditions like sepsis. Unlike traditional positive/negative tests, this innovation provides quantitative results at the point-of-care, eliminating the need for laboratory processing.
The company plans to advance the SUMMIT program by developing a finger-prick version using capillary blood for broader applications.
VolitionRx (NYSE: VNRX), a multi-national epigenetics company, reported its Q1 2025 financial results and business updates. The company recorded $0.25 million in revenue, up 44% year-over-year, while reducing monthly net cash burn to $1.4 million, a 50% reduction from Q1 2024.
Key highlights include ongoing confidential discussions with over ten companies for Nu.Q® platform commercialization in human diagnostics, with seven potential partners having a combined market value exceeding $600 billion. The company achieved its first revenue from CE-marked Nu.Q® NETs automated product sales in Europe during Q1 2025.
Financial position shows cash and equivalents of $2.6 million as of March 31, 2025, with additional funding of $4.3 million received in Q1 and a subsequent $6.25 million convertible loan note. VolitionRx aims to achieve cash neutrality for full-year 2025.
VolitionRx Limited (NYSE AMERICAN: VNRX) has scheduled its First Quarter 2025 Earnings Conference Call and Business Update for Friday, May 16, 2025, at 8:30 a.m. U.S. Eastern Time. The call will be hosted by Louise Batchelor (Group Chief Marketing & Communications Officer), Cameron Reynolds (President and Group CEO), and Terig Hughes (Group CFO).
The conference call will discuss Q1 2025 financial and operating results, recent important events, and upcoming milestones. Participants can join via multiple channels including U.S. & Canada toll-free (1-877-407-9716), U.K. toll-free (0 800 756 3429), or international dial-in (1-201-493-6779). A live audio webcast will be available, and a replay will be accessible until May 30, 2025.
VolitionRx Limited (VNRX) has outlined its strategy to become the global leader in NETs (NETosis) testing through a two-pronged approach. First, the company is in confidential licensing discussions with seven international companies (six valued at nearly $600 billion combined) to launch their Nu.Q® NETs test on existing hospital machines. Second, they're leveraging their CE-marked Nu.Q® NETs test, which has already generated its first revenue in Q1 2025 with nine hospital networks across five European countries implementing the test.
The company estimates the Total Addressable Market for Intensive Care Patients testing alone at $1 billion annually, with potential to exceed $10 billion as applications expand. The Nu.Q® NETs test is being evaluated for multiple clinical applications, including sepsis management, cardiac disease, burns, autoimmune diseases, and pregnancy management. The company's strategy mirrors their successful veterinary market approach, aiming for multiple licensing agreements with ongoing revenue and milestone payments.
VolitionRx (NYSE: VNRX) announces significant progress in commercializing its Nu.Q® platform for both human and veterinary diagnostics. CEO Cameron Reynolds reports confidential discussions with over 10 companies, including seven with a combined market value exceeding $600 billion.
The company's focus areas include cancer diagnostics and sepsis monitoring, representing a $25 billion annual market opportunity. Recent achievements include:
- Raised $4.2 million through direct offerings in December 2024 and March 2025
- Advanced lung cancer screening study in Taiwan with 60 patients enrolled
- Secured first revenue for CE-Marked Nu.Q® NETs product in Europe
- Expanded veterinary partnerships with Antech, FujiFilm Vet Systems, and IDEXX
- Achieved first commercial sale of High Throughput Synthetic Sepsis Model
The company aims to secure multiple licensing agreements in human diagnostics during 2025, following their successful veterinary market strategy. Their Nu.Q® platform shows broad applicability in critical disease areas, supported by strong clinical evidence and a substantial patent portfolio.
VolitionRx (NYSE: VNRX) reported its full fiscal year 2024 results, achieving $1.2 million in revenue, a 59% increase from the previous year. The company's Nu.Q® Vet revenue grew 75% while Nu.Q® Discover revenue increased 40% compared to 2023.
Key operational highlights include the sale of approximately 120,000 Nu.Q® Vet Cancer Tests in 2024 and expansion to over 20 countries. Operating expenses decreased by 23% year-over-year, with second-half expenses down 31%. The company ended 2024 with $3.3 million in cash and subsequently received $1.8 million in non-dilutive funding from Belgian institutions and raised $2.3 million through a registered direct offering.
The company is advancing commercial discussions with major players in human diagnostics and liquid biopsy for sepsis and oncology markets, aiming to secure multiple licensing deals in 2025. Volition targets cash neutrality in 2025, expecting income, including licensing receipts, to match expenditure.
VolitionRx (NYSE AMERICAN: VNRX) announces two significant poster presentations at ESMO's European Lung Cancer Congress (ELCC) 2025 in Paris. The presentations focus on the company's innovative biomarker technologies:
1. The Nu.Q® H3K27Me3 biomarker, combined with circulating tumor DNA, shows potential to improve prognostic value for overall survival and treatment decision-making in Non Small Cell Lung Cancer (NSCLC).
2. The Nu.Q® H3.1 low-cost immunoassay demonstrates potential for early identification of high-risk cancer subjects.
The presentations, scheduled for March 28, 2025, include studies on early detection of stage I/II NSCLC and H3K27Me3-nucleosome as a prognostic biomarker in NSCLC, with analysis of up to 832 patients at baseline.